🇺🇸 FDA
Pipeline program

Cariprazine

RGH-MD-25

Phase 3 small_molecule completed

Quick answer

Cariprazine for Bipolar I Disorder is a Phase 3 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie
Indication
Bipolar I Disorder
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials